PanPeptide™ Platform

Accelerate multi-targeting peptide drug discovery with our 3D-structured peptide library platform.

Platform Overview

PanPeptide™ Platform: Unlocking the Future of Multi-Targeting Peptide Therapeutics

Traditional peptide discovery methods—whether natural source isolation or conventional display libraries—are limited by insufficient structural and sequence diversity. Protheragen addresses this critical gap with PanPeptide™, our innovative multi-targeting peptide drug discovery platform built upon a proprietary 3D-structured massive peptide library that integrates sequence diversity, structural diversity, and library size. By integrating all three dimensions of diversity, PanPeptide™ enables the efficient discovery of high-affinity, multi-functional peptides capable of targeting complex diseases, opening new horizons for therapeutic innovation.

Disruptive Technology
Excellent Team
Diversified Pipeline
Customized Solutions

Platform Core

3D-Structured Massive Peptide Library

The 3D-structured massive peptide library is meticulously arrayed in a 96-well plate format, comprising:

More than 1,200 individual 96-well plates
Each well containing a small, structurally distinct peptide library
Each small library housing approximately 1,000 peptides
Over 100 million synthetic peptides in total
Fully compatible with any standard high-throughput screening (HTS) system

This innovative format integrates three essential dimensions of diversity including structural diversity, sequence diversity, and library size diversity into a single, HTS-ready platform.

Sequence diversity is achieved through:

Non-natural amino acids for enhanced proteolytic stability and novel binding modalities
Fluorescence labeling options for direct screening without secondary detection steps
D-amino acids to improve metabolic stability and create protease-resistant peptides
More than 100 million synthesized peptides covering vast chemical space
100,000+ small peptide libraries enabling focused screening against specific target classes

Platform Advantages

Unique Advantages of the PanPeptide™ Platform

Multi-Targeting Capability

The synergistic combination of structural, length, and sequence diversity enables the discovery of peptides capable of engaging multiple disease-relevant targets simultaneously. This multi-targeting approach is particularly valuable for addressing complex, network-driven diseases such as cancer and autoimmune disorders, offering higher efficacy and reduced resistance.

Unparalleled Structural Diversity

Our library encompasses a comprehensive spectrum of peptide architectures—linear, cyclic, branched, bicyclic, tricyclic, and proprietary novel structures. This structural richness enables the discovery of peptides with unique binding modes, enhanced proteolytic stability, and improved bioavailability that conventional linear libraries cannot achieve.

Broad Size Diversity

The library covers a full spectrum of peptide lengths ranging from 2 to 30 amino acids, enabling the discovery of both short peptides with high stability and tissue penetration, and longer peptides capable of forming complex tertiary structures for challenging targets.

Vast Sequence Space

With over 100 million synthesized peptides organized into 100,000+ mini-libraries, PanPeptide™ incorporates non-natural amino acids, D-amino acids, and fluorescence labeling options. This expansive sequence diversity maximizes the probability of identifying high-affinity hits against even the most challenging therapeutic targets.

Tag-Free Native Screening

All peptides are presented without fusion tags, immobilization, or chemical modifications that could interfere with target binding. This tag-free approach eliminates false positives caused by steric hindrance and ensures that screening data accurately reflects native peptide-target interactions.

Platform Application

Multi-Targeting Drug Discovery: Empowering Therapies Across Diverse Diseases

Oncology Targeting Peptides Our platform has discovered high-affinity peptides against diverse cancer targets, including anti-hypoxia peptides for tumor microenvironment targeting and cell-penetrating peptides (CPPs) for intracellular delivery. We have also identified RDCs specifically targeting small cell lung cancer (SCLC). These candidates demonstrate potent tumor selectivity and enhanced tissue penetration.
Autoimmune Disease Therapeutics PanPeptide™ enables discovery of immunomodulatory peptides that regulate key autoimmune pathways. By targeting pathogenic immune cells and inflammatory mediators, we have identified promising candidates for rheumatoid arthritis, inflammatory bowel disease, and lupus. These peptides offer high specificity while minimizing systemic immunosuppression.
Blood-Brain Barrier (BBB) Targeting PanPeptide™ has yielded structurally unique peptides capable of crossing the blood-brain barrier, opening new avenues for central nervous system (CNS) disorders. These BBB-targeting peptides function as standalone biologics or as carriers for delivering therapeutic payloads to the brain, addressing a key challenge in CNS drug development.

Pipeline

Research & Development Pipeline

Leveraging our comprehensive peptide library and multi-targeting drug discovery platform, we are developing bioactive peptide drug candidates targeting cancer and autoimmune disorders. Our current pipeline includes multifunctional peptides designed to modulate immune checkpoints, cytokines, and immunoregulatory factors, offering novel therapeutic approaches for complex diseases.

Projects	Therapy Types	Target	Indication
PDP004	Mono-Target Peptide	To be disclosed	Solid Tumors
PDP012	Mono-Target Peptide	To be disclosed	Autoimmune Diseases
PDP017	Mono-Target Peptide	To be disclosed	Autoimmune Diseases
PDP025	Multi-Target Peptide	To be disclosed	Solid Tumors
PDP028	Multi-Target Peptide	To be disclosed	Autoimmune Diseases
PDP033	Multi-Target Peptide	To be disclosed	Solid Tumors
PDP036	Multi-Target Peptide	To be disclosed	Solid Tumors

Get in Touch with Us

FAQs

Frequently Asked Questions

Q1: What makes PanPeptide™ different from phage display or mRNA display libraries? A: Unlike phage or mRNA display that typically screen linear peptides requiring post-selection folding, PanPeptide™ features pre-folded 3D peptide structures. This structural pre-organization significantly enriches for functionally relevant hits and improves downstream development success rates.
Q2: How many peptides are in the PanPeptide™ library? A: The platform contains over 100 million synthetic peptides, strategically distributed across 1,200+ 96-well plates, with each well housing a mini-library of approximately 1,000 structurally diverse peptides.
Q3: Can I use my existing HTS equipment with PanPeptide™? A: Yes, our 96-well plate format is fully compatible with standard high-throughput screening instruments, allowing seamless integration into your existing workflow without additional capital investment.
Q4: What types of targets have been successfully screened using PanPeptide™? A: We have successfully identified high-affinity peptides against a broad range of immunologically relevant targets, including immune response biomarkers, immune regulators and cytokines, and immune checkpoints. In addition, our platform has yielded structurally unique peptides capable of targeting blood-brain barrier (BBB) receptors, enabling the development of therapeutics for central nervous system disorders. These discoveries demonstrate the platform's versatility in addressing challenges across cancer immunotherapy, autoimmune disorders, inflammatory diseases, and CNS drug delivery.
Q5: Are the peptides in your library tag-free? A: Absolutely. All peptides are presented without tags, immobilization, or modifying groups, ensuring that screening results reflect true native interactions and eliminating tag-related artifacts.